Antitumor mechanism of metformin and its effect on targeted drugs

doi:10.3760/cma.j.issn.1673-422X.2018.12.010

Abstract

Abstract: With the advent of the era of accurate medical treatment, molecular targeted therapy has become a new trend of cancer treatment. The abnormal status of cancer metabolism and metabolic drug together with tumor targeted therapy are becoming the hotspot in cancer. A large number of studies have shown that metformin, a targeted metabolic drug, has synergistic antitumor effects when it is used in combination with various target drugs. The combination of targeted metabolic drugs and antitumor drugs can provide new strategies for tumor treatment.

Key words: Metformin, Neoplasms, Targeted drugs

Gao Hui, Yi Shanyong, Yang Bin, Ma Xiwen, Zhao Ling. Antitumor mechanism of metformin and its effect on targeted drugs[J]. Journal of International Oncology, 2018, 45(12): 747-750.

References

［1］ Warburg O. On the origin of cancer cells［J］. Science, 1956, 123(3191): 309314. DOI: 10.1126/science.123.3191.309. ［2］ Chae YK, Arya A, Malecek MK, et al. Repurposing metformin for cancer treatment: current clinical studies［J］. Oncotarget, 2016, 7(26): 4076740780. DOI: 10.18632/oncotarget.8194. ［3］ Buckanovich RJ, Brown J, Shank J, et al. A phase Ⅱ clinical trial of metformin as a cancer stem cell targeting agent in stage Ⅱc/Ⅲ/Ⅳ ovarian, fallopian tube, and primary peritoneal cancer［J］. Clin Oncol, 2017, 35(Suppl): 5556．［4］ Howell JJ, Ricoult SJ, BenSahra I, et al. A growing role for mTOR in promoting anabolic metabolism［J］. Biochem Soc Trans, 2013, 41(4): 906912. DOI: 10.1042/BST20130041. ［5］ Hawley SA, Gadalla AE, Olsen GS, et al. The antidiabetic drug metformin activates the ampactivated protein kinase cascade via an adenine nucleotideindependent mechanism［J］. Diabetes, 2002, 51(8): 24202425. DOI: 10.2337/diabetes.51.8.2420. ［6］ Brower V. Illuminating the diabetescancer link［J］. Natl Cancer Inst, 2012, 104(14): 10481050. DOI: 10.1093/jnci/djs322. ［7］ Buzzai M, Jones R, Amaravadi R, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53deficient tumor cell growth［J］. Cancer Res, 2007, 67(14): 67456752. DOI: 10.1158/00085472.CAN064447. ［8］ Wang Y, Lin D, Wang X, et al. Data on water consumption in streptozotocininduced diabetic mice by a novel peach gumderived polysaccharide［J］. Data Brief, 2017, 12: 358360. DOI: 10.1016/j.dib.2017.04.022. ［9］ Iliopoulos D, Hirsch HA, Struhl K. Metfomin decreases the dose of chemotherapy for pmlonging tumor remission in mouse xenograftsinvolving multiple cancer ceu types［J］. Cancer Res, 2011, 7l(9): 31963201. DOI: 10.1158/00085472.CAN103471. ［10］ Arrieta O, Barron FB, Padilla MS, et al. Combination of metformin plus TKI vs. TKI alone in EGFR(+) lung adenocarcinoma: a randomized phase Ⅱ study［J］. J Clin Oncol, 2018, 36(suppl): abstr 9013. ［11］ Chen H, Yao W, Chu Q, et al. Synergistic effects of metformin in combination with EGFRTKI in the treatment of patients with advanced nonsmall cell lung cancer and type 2 diabetes［J］. Cancer Lett, 2015, 369(1): 97102. DOI: 10.1016/j.canlet.2015.08.024. ［12］ Pan YH, Jiao L, Lin CY, et al. Combined treatment with metformin and gefitinib overcomes primary resistance to EGFRTKIs with EGFR mutation via targeting IGF1R signaling pathway［J］. Biologics, 2018, 12: 7586. DOI: 10.2147/BTT.S166867. ［13］ Li L, Han R, Xiao H, et al. Metformin sensitizes EGFRTKIresistant human lung cancer cells in vitro and in vivo through inhibition of IL6 signaling and EMT reversal［J］. Clin Cancer Res, 2014, 20(10): 27142726. DOI: 10.1158/10780432.CCR132613. ［14］ Li C, Xue Y, Xi YR, et al. Progress in the application and mechanism of metformin in treating nonsmall cell lung cancer［J］. Oncol Lett, 2017, 13(5): 28732880. DOI: 10.3892/ol.2017.5862. ［15］ Groenendijk FH, Mellema WW, van der Burg E, et al. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation［J］. Int J Cancer, 2015, 136(6): 14341444. DOI: 10.1002/ijc.29113. ［16］ Casadei Gardini A, Faloppi L, De Matteis S, et al. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: validation study and biological rationale［J］. Eur J Cancer, 2017, 86: 106114. DOI: 10.1016/j.ejca.2017.09.003. ［17］ Hsieh SC, Tsai JP, Yang SF, et al. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNKmediated NFκBdependent pathway that reduces uPA and MMP9 expression［J］. Amino Acids, 2014, 46(12): 28092822. DOI: 10.1007s0072601418384. ［18］ VazquezMartin A, OliverasFerraros C, DelBarco S, et al. The antidiabetic drug metformin suppresses selfrenewal and proliferation of trastuzumabresistant tumorinitiating breast cancer stem cells［J］. Breast Cancer Res Treat, 2011, 126(2): 355364. DOI: 10.1007/s105490100924x. ［19］ Cufi S, CorominasFaja B, VazquezMartin A, et al. Metformininduced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts［J］. Oncotarge, 2012, 3(4): 395398. DOI: 10.18632/oncotarget.488. ［20］ Sonnenblick A, AgborTarh D, Bradbury I, et al. Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2positive primary breast cancer: analysis from the ALTTO phase Ⅲ randomized trial［J］. Clin Oncol, 2017, 35(13): 14211429. DOI: 10.1200/JCO.2016.69.7722. ［21］ Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission［J］. Cancer Res, 2009, 69(19): 75077511. DOI: 10.1158/00085472.CAN092994. ［22］ Scharping NE, Menk AV, Whetstone RD, et al. Efficacy of PD1 blockade is potentiated by metformininduced reduction of tumor hypoxia［J］. Cancer Immunol Res, 2017, 5(1): 916. DOI: 10.1158/23266066.CIR160103. ［23］ Eikawa S, Nishida M, Mizukami S, et al. Immunemediated antitumor effect by type 2 diabetes drug, metformin［J］. Proc Natl Acad Sci U S A, 2015, 112(6): 18091814. DOI: 10.1073/pnas.1417636112. ［24］ Watanabe M, Yamamoto H, Eikawa S, et al. Study about the efficacy of metformin to immune function in cancer patients［J］. Acta Med Okayama, 2016, 70(4): 327330. DOI: 10.18926AMO/54514. ［25］ Afzal MZ, Mercado RR, Shirai K, et al. Efficacy of metformin in combination with immune checkpoint inhibitors (antiPD1/antiCTLA4) in metastatic malignant melanoma［J］. J Immunother Cancer, 2018, 6(1): 64. DOI: 10.1186/s4042501803751. ［26］ Kubo T, Ninomiya T, Hotta K, et al. Study protocol: phaseⅠb trial of nivolumab combined with metformin for refractory/recurrent solid tumors［J］. Clin Lung Cancer, 2018, 19(6): e861e864. DOI: 10.1016/j.cllc.2018.07.010. ［27］ Hirsch HA, Iliopoulo D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth［J］. Proc Natl Acad Sci U S A, 2013, 110(3): 972977. DOI: 10.1073/pnas.1221055110.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.